ABCB1 allele polymorphism is associated with virological efficacy in naïve HIV- infected patients on HAART containing nonboosted pls but not boosted pls

HIV Clinical Trials

Volumn 9, Issue 3, 2008, Pages 192-201

  De La Tribonniere X ^a   Broly, F ^b   Deuffic Burban, S ^c   Bocket, L ^b   Ajana, F ^a   Viget, N ^a   Melliez, H ^a   Mouton, Y ^a   Yazdanpanah, Y ^a,c,d  

^a Tourcoing Hospital   (France)

^b UNIV LILLE   (France)

^c IESEG School of Management   (France)

^d UNIV LILLE   (France)

Author keywords

ABCB1; AIDS; Antiretroviral; C3435T; HIV; MDR; Protease inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ABCB1 GENE; ADULT; ARTICLE; FEMALE; GENE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 45949102313     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0903-192     Document Type: Article

References (34)

1. Sharom FJ, Yu X, Doige CA. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem. 1993;268:24197-24202.
2. Sankatsing SU, Cornelissen M, Kloosterboer N, Crommentuyn KM, Bosch TM, Mul FP, et al. Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. AIDS Res Hum Retroviruses. 2007;23:19-27.
3. Gupta S, Kim CH, Tsuruo T, Gollapudi S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol. 1992;12:451-458.
4. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brock-moller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-3478.
5. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002;25:1391-1400.
6. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz Ul, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
7. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-36.
8. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS. 2005;19:371-380.
9. Zhu D, Taguchi-Nakamura H, Goto M, Odawara T, Nakamura T, Yamada H, et al. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir Ther. 2004; 9:929-935.
10. Owen A, Chandler B, Back DJ. The implications of Pglycoprotein in HIV: friend or foe? Fund Clin Pharmacol. 2005;19:283-296.
11. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS. 2003;17:1696-1698.
12. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS. 2003;17:201-208.
13. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naive HIV-positive patients. Ann Clin Microbiol Antimicrob. 2005;4:3.
14. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis. 2005;192:1931-1942.
15. Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentre F, et al. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS. 2005;19:2127-2131.
16. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007; 7:154-179.
17. Bocket L, Cheret A, Deuffic-Burban S, Choisy P, Gerard Y, de la Tribonniere X, et al. Impact of human immuno-deficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther. 2005;10:247-254.
18. Yazdanpanah Y, Chene G, Losina E, Goldie SJ, Merchadou LD, Alfandari S, et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol. 2001 ;30:864-871.
19. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001 ;11:217-221.
20. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001;358:383-384.
21. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003;34:295-298.
22. Solas C, Simon N, Drogoul MR Quaranta S, Frixon-Marin V, Bourgarel-Rey V, et al. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol. 2007; 64:353-362.
23. la Porte CJ, Li Y, Beique L, Foster BC, Chauhan B, Garber GE, et al. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clin Pharmacol Ther. 2007;82:389-395.
24. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovu-dine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006;42:441-449.
25. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, et al. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics. 2005;15:599-608.
26. Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007;60:987-993.
27. Lucia MB, Rutella S, Leone G, Vella S, Cauda R. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr. 2001;27:321-330.
28. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007;73:1573-1581.
29. Chaillou S, Durant J, Garraffo R, Georgenthum E, Roptin C, Dunais B, et al. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials. 2002;3:493-501.
30. Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter Pglycoproteins. Biol Pharm Bull. 2000;23:1528-1531.
31. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A quot;silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525-528.
32. Parmley JL, Hurst LD. How do synonymous mutations affect fitness? Bioessays. 2007;29:515-519.
33. Komar AA. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics. 2007;8:1075-1080.
34. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-166.